常州大学学报（自然科学版）2024，Vol.36Issue(6)：90-97,8.DOI:10.3969/j.issn.2095-0411.2024.06.011
免疫检查点抑制剂相关肾上腺损伤病例分析
Case analysis adrenal damage associated with immune checkpoint inhibitors
徐文东 1陶静怡 2李菁 3吴萍 3房灏3
作者信息
- 1. 常州市第一人民医院 内分泌代谢科,江苏 常州 213003
- 2. 常州大学 药学院,江苏 常州 213164
- 3. 常州市第一人民医院 药学部,江苏 常州 213003
- 折叠
摘要
Abstract
A descriptive statistical analysis was conducted on patients with adrenal insufficiency caused by immune checkpoint inhibitors(ICIs)admitted to The First People's Hospital of Changzhou from January 2018 to April 2024.The analysis covered the patients'basic demographics,tumor characteris-tics,clinical manifestations,treatment,and outcomes to explore the clinical features of adrenal insuf-ficiency in cancer patients using ICIs.A total of 13 patients were included in the study,comprising 11 males(84.6%)and 2 females(15.4%),with a median age of 66 years old.The median treatment cy-cle before the onset of drenocortical insufficiency was 11,with a median duration of 266 d from the ad-ministration of ICIs.According to the Common Terminology Criteria for Adverse Events by the Na-tional Cancer Institute,84.6%of cases were severe(≥Grade 3).13 patients discontinued ICIs after the occurance of adrenal insufficiency,and the antitumor drug of one patient was switched to PD-L1 therapy without adrenal insufficiency recurrence.13 patients were treated with glucocorticoids and re-mained clinically stable.In summary,adrenal insufficiency predominantly occurs in elderly patients,with severe clinical symptoms being most common.The prognosis is generally good following the dis-continuation of ICIs and the administration of glucocorticoid therapy.In selected cases,other drugs of ICIs may be safely selected under close monitoring after weighing the benefits and risks.关键词
免疫检查点抑制剂/肾上腺皮质功能减退症/回顾性研究/免疫相关不良事件Key words
immune checkpoint inhibitors/adrenocortical insufficiency/retrospective study/immune-related adverse events分类
医药卫生引用本文复制引用
徐文东,陶静怡,李菁,吴萍,房灏..免疫检查点抑制剂相关肾上腺损伤病例分析[J].常州大学学报（自然科学版）,2024,36(6):90-97,8.
